Prevalence and risk factors for severe linezolid-associated thrombocytopenia in pediatric patients: An analysis of a public database

Yang, Seung-Han; Guo, Wencheng; Chen, Ming; Hu, Jindong; Feng, Na; Ju, Mohan; Qian, Yue

doi:10.1097/md.0000000000034059

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar nding was reported for low baseline platelet count by Duan et al in neonates [47] and by Choi et al in adults [51], and by Thi Phuong et al for sepsis/septic shock in adults [52]. Other studies demonstrated that the concomitant use of meropenem, piperacillin/tazobactam, levo oxacin, or caspofungin was a risk factor for the development of thrombocytopenia in patients receiving linezolid [53][54][55]. It was an anticipated nding that the number of patients receiving meropenem and linezolid combination therapy in ICU patients would be higher than other combination therapies considering the antimicrobial resistance pro le of the ICUs.…”

Section: Discussionsupporting

confidence: 78%

Evaluation of Pharmacokinetic Pharmacodynamic Target Attainment and Hematological Toxicity of Linezolid in Pediatric Patients

Abouelkheir,

Aldawsari,

Ghonem

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Linezolid is commonly used to treat severe and/or resistant Gram-positive infections. Few studies have assessed its pharmacokinetics/pharmacodynamics (PK/PD) in pediatrics. Objective to evaluate the percentage of pediatric patients achieving the PK/PD target of linezolid using standard dosing regimens and to assess the incidence and risk factors associated with its hematologic toxicity. Methods This prospective observational study included pediatric patients aged 0–14 years who received linezolid for suspected or proven Gram-positive infections. Linezolid trough concentrations were measured, and hematologic toxicity was assessed. Results In total, 17 pediatric patients (5 neonates and 12 older pediatrics) were included in the analysis. The median trough concentration in neonates was significantly higher than that of the older pediatrics (7.1 [6.2–11.0] vs. 3.9 [1.95–6.5] mg/L, respectively, P = 0.04). Out of all patients, 53% achieved the therapeutic trough level of 2–7 mg/L, 18% had subtherapeutic levels, and 23% had higher-than-optimal troughs. Linezolid-associated hematological toxicity was documented in 53% of cases. Identified significant risk factors include treatment duration of more than 7 days, baseline platelet counts of less than 150 x 109/L, sepsis/septic shock, and concomitant use of meropenem. Conclusions Linezolid's standard dosing failed to achieve its PK/PD target in approximately half of our pediatric cohort. Our findings underscore the complex interplay between the risk factors of linezolid-associated hematological toxicity and highlight the importance of its vigilant use and monitoring if it is to be initiated in pediatrics with concomitant multiple risk factors.

show abstract